


5

ABSTRACT

A compound comprising




or a pharmaceutically acceptable salt or a prodrug thereof,

10 wherein

the dashed line represents the presence or absence of a double bond;

J is C=O or CHOH;

A is $-(CH_2)_6-$, or *cis* $-CH_2CH=CH-(CH_2)_3-$, wherein 1 or 2 carbons may be substituted with S or O;15 B is CO_2H , or CO_2R , $CONR_2$, $CONHCH_2CH_2OH$, $CON(CH_2CH_2OH)_2$, CH_2OR , $P(O)(OR)_2$, $CONRSO_2R$, $SONR_2$, orR is H, C_{1-6} alkyl;D is $-(CH_2)_n-$, $-X(CH_2)_n$, or $-(CH_2)_nX-$, wherein n is from 0 to 3 and X is S or O;

20 and

E is an aromatic or heteroaromatic moiety having from 0 to 4 substituents, said substituents each comprising from 1 to 6 non-hydrogen atoms is disclosed herein. Methods, compositions, and medicaments related thereto, as well as experimental results showing prostaglandin EP4 selective agonist activity for

25 certain compounds disclosed herein, are also disclosed.